ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients

Pharmacogenomics

Volumn 14, Issue 14, 2013, Pages 1723-1730

  Huang, Xiaoye ^a,b   Yu, Tao ^a,b   Li, Xin ^a,b   Cao, Yanfei ^a,b   Li, Xingwang ^a,b,c   Liu, Baocheng ^a,b   Yang, Fengping ^a,b   Li, Weidong ^a,b   Zhao, Xinzhi ^c   Feng, Guoyin ^d   Zhang, Xu ^e   Dong, Zaiquan ^e   He, Lin ^a,b,c   Sun, Xueli ^e   He, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

ABCB1; ABCB6; ABCG1; Major depressive disorder; Pharmacogenetics; SSRIs

Indexed keywords

ABC TRANSPORTER B6; ABC TRANSPORTER G1; CITALOPRAM; FLUOXETINE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCB6 PROTEIN, HUMAN; ABCG1 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ABCB6 GENE; ABCG1 GENE; ADULT; ARTICLE; CHINESE HAN; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HUMAN; LIFE EVENTS SCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CHINA; DEPRESSIVE DISORDER, MAJOR; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHINA; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS;

EID: 84897048475     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.151     Document Type: Article

References (43)

1. Lépine JP. Epidemiology, burden, and disability in depression and anxiety. J. Clin. Psychiatry 62(Suppl. 13), 4-12 (2001).
2. Licinio J, Wong ML. Advances in depression research: 2011. Mol. Psychiatry 16(7), 686-687 (2011).
3. Brådvik L, Mattisson C, Bogren M, Nettelbladt P. Long-term suicide risk of depression in the Lundby cohort 1947-1997 -severity and gender. Acta Psychiatr. Scand. 117(3), 185-191 (2008).
4. Bender A, Farvolden P. Depression and the workplace: a progress report. Curr. Psychiatry Rep. 10(1), 73-79 (2008).
5. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631), 386-389 (2003).
6. Lieberman J. History of the use of antidepressants in primary care. Prim. Care Companion J. Clin. Psychiatry 5(Suppl. 7), S6-S10 (2003).
7. Best J, Nijhout HF, Reed M. Bursts and the efficacy of selective serotonin reuptake inhibitors. Pharmacopsychiatry 44(Suppl. 1), S76-S83 (2011).
8. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int. J. Clin. Pract. 61(4), 702-710 (2007).
9. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905-1917 (2006).
10. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int. J. Neuropsychopharmacol. 5(3), 255-275 (2002).
11. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet. Genomics 15(2), 61-67 (2005).
12. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55(1), 3-29 (2003).
13. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27(1), 85-105 (2012).
14. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 68(1), 98-103 (2000).
15. Virgintino D, Robertson D, Errede M et al. Expression of caveolin-1 in human brain microvessels. Neuroscience 115(1), 145-152 (2002).
16. Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77(4), 491-502 (1994).
17. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin. Neurosci. 64(5), 447-459 (2010).
18. de Klerk O, Nolte I, Bet P et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 13(4), 349-353 (2012).
19. Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(2), 398-404 (2008).
20. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 14(12), 1105-1118 (2009).
21. Lin KM, Chiu YF, Tsai IJ et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet. Genomics 21(4), 163-170 (2011).
22. Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR* D sample. PLoS ONE 3(4), e1872 (2008).
23. Crisafulli C, Chiesa A, Han C et al. Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Res. 209(1), 121-123 (2012).
24. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27(2), 187-196 (2012).
25. Di Martino MT, Arbitrio M, Leone E et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol. Ther. 12(9), 780-787 (2011).
26. Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57(2), 203-209 (2008).
27. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15(2), 97-98 (2005).
28. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59(1), 97-105 (1995).
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
30. Li Z, Zhang Z, He Z et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 19(4), 519-523 (2009).
31. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11(7), 1156-1166 (2001).
32. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580(4), 998-1009 (2006).
33. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 239(2), 168-182 (2006).
34. Ambudkar SV, Lelong IH, Zhang J, Cardarelli C. Purification and reconstitution of human P-glycoprotein. Methods Enzymol. 292, 492-504 (1998).
35. Fujii T, Ota M, Hori H et al. Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J. Psychiatr. Res. 46(4), 555-559 (2012).
36. Ishikawa T, Sakurai A, Hirano H, Lezhava A, Sakurai M, Hayashizaki Y. Emerging new technologies in pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC transporter ABCB1 (P-gp/MDR1). Pharmacol. Ther. 126(1), 69-81 (2010).
37. Ishikawa T, Tsuji A, Inui K et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5(1), 67-99 (2004).
38. Chavan H, Oruganti M, Krishnamurthy P. The ATP-binding cassette transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. Toxicol. Sci. 120(2), 519-528 (2011).
39. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49(5), 610-617 (2005).
40. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 37(3), 179-185 (2003).
41. Kapoor A, Iqbal M, Petropoulos S, Ho HL, Gibb W, Matthews SG. Effects of sertraline and fluoxetine on P-glycoprotein at barrier sites: in vivo and in vitro approaches. PLoS ONE 8(2), e56525 (2013).
42. dbSNP database. www.ncbi.nlm.nih.gov/SNP
43. SHEsis. http://202.120.31.177/myanalysis.php